{"database":"ENA","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Fastqsanger.gz":["ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR670/007/SRR6705537/SRR6705537_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR670/001/SRR6705541/SRR6705541_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR670/000/SRR6705540/SRR6705540_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR670/008/SRR6705538/SRR6705538_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR670/009/SRR6705539/SRR6705539_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR670/000/SRR6705540/SRR6705540_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR670/007/SRR6705537/SRR6705537_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR670/001/SRR6705541/SRR6705541_1.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR670/009/SRR6705539/SRR6705539_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR670/008/SRR6705538/SRR6705538_2.fastq.gz"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["Genomics, Bioinformatics, The Wistar Institute"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA433734"],"scientific_name":["Homo sapiens"],"tag":["xref:PubMed:30297712"],"long_description":["The SWI/SNF chromatin remodeling complex is altered in ~20% of human cancers. ARID1A, a component of the SWI/SNF chromatin-remodeling complex, is the most frequently mutated epigenetic regulator in human cancers. Inactivation of the SWI/SNF complex is synthetically lethal with inhibition of EZH2 activity. EZH2 inhibitors are entering clinical trials for specific tumor types with SWI/SNF mutations. However, mechanisms of de novo or acquired resistance to EZH2 inhibitors in cancers with inactivating SWI/SNF mutations are unknown. Here we show that the switch of the SWI/SNF catalytic subunits from SMARCA4 to SMARCA2 drives resistance to EZH2 inhibitors in ARID1A-mutated ovarian cancer cells. Overall design: Parental TOV21G cell line and and resistant to EZH2 inhibitor GSK126 treatment clones were assayed by RNA-seq and BRG1 CHIP-seq"],"repository":["ENA"],"additional_accession":[]},"is_claimable":false,"name":"Catalytic subunits switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells [RNA-seq]","description":"Catalytic subunits switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells [RNA-seq]","dates":{"last_updated":"2025-09-24","first_public":"2019-02-11"},"accession":"PRJNA433734","cross_references":{"GEO":["GSE110449"],"taxon":["9606"],"PubMed":["30297712"]}}